Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported ...

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the ...

The Alliance for Regenerative Medicine’s (ARM) Cell & Gene Meeting on the Med, took place in Barcelona back in April. ABL Biomanufacturing - a pure play Contract Development and Manufacturing ...

This inhibitor is designed to specifically target the BCR-ABL gene fusion. It has an Orphan Drug designation and is currently being evaluated in a Phase 1 trial to treat chronic myeloid leukemia ...

Learn about April 2025’s top biotech deals, featuring major collaborations in bispecific antibodies, protein therapies, and ...

The blood cancer market is experiencing robust growth, driven by rising incidence rates and advancements in targeted therapies and immuno-oncology. I ...

Oxford Bio’s recently-appointed chief executive, Dr Frank Mathias, said buying ABL would contribute to the company’s strategy to transition to a pure-play CDMO focusing on the cell and gene ...

First quarter 2025 Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue declined by 20% year-over-year ...

The continued availability and amount thereof under the ABL Facility is subject to maintaining ... UnitedHealthcare's decision to discontinue coverage of multi-gene panel pharmacogenetic testing ...

Q1 2025 Earnings Conference Call May 1, 2025 11:00 AM ETCompany ParticipantsGene Shiels - Director of IRKurt Bitting - ...